<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sheward DJ</submitter><funding>NIAID NIH HHS</funding><pagination>101577</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11228396</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(6)</volume><pubmed_abstract>Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using "public" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA.1, BA.2, and BA.4/BA.5 sublineages of Omicron. Deep mutational scanning reveals </pubmed_abstract><journal>Cell reports. Medicine</journal><pubmed_title>Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.</pubmed_title><pmcid>PMC11228396</pmcid><funding_grant_id>R01 AI141707</funding_grant_id><pubmed_authors>Kim C</pubmed_authors><pubmed_authors>Peacock TP</pubmed_authors><pubmed_authors>Dopico XC</pubmed_authors><pubmed_authors>Greaney AJ</pubmed_authors><pubmed_authors>Lee J</pubmed_authors><pubmed_authors>Sheward DJ</pubmed_authors><pubmed_authors>Corcoran M</pubmed_authors><pubmed_authors>Hallberg BM</pubmed_authors><pubmed_authors>Kim S</pubmed_authors><pubmed_authors>Murrell B</pubmed_authors><pubmed_authors>Dosenovic P</pubmed_authors><pubmed_authors>Bloom JD</pubmed_authors><pubmed_authors>Das H</pubmed_authors><pubmed_authors>Pushparaj P</pubmed_authors><pubmed_authors>Albert J</pubmed_authors><pubmed_authors>Hyllner E</pubmed_authors><pubmed_authors>Dyrdak R</pubmed_authors><pubmed_authors>Hanke L</pubmed_authors><pubmed_authors>McInerney GM</pubmed_authors><pubmed_authors>Karlsson Hedestam GB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.</name><description>Descendants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant now account for almost all SARS-CoV-2 infections. The Omicron variant and its sublineages have spike glycoproteins that are highly diverged from the pandemic founder and first-generation vaccine strain, resulting in significant evasion from monoclonal antibody therapeutics and vaccines. Understanding how commonly elicited antibodies can broaden to cross-neutralize escape variants is crucial. We isolate IGHV3-53, using "public" monoclonal antibodies (mAbs) from an individual 7 months post infection with the ancestral virus and identify antibodies that exhibit potent and broad cross-neutralization, extending to the BA.1, BA.2, and BA.4/BA.5 sublineages of Omicron. Deep mutational scanning reveals </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2026-06-01T07:37:28.23Z</modification><creation>2025-04-04T11:25:08.643Z</creation></dates><accession>S-EPMC11228396</accession><cross_references><pubmed>38761799</pubmed><doi>10.1016/j.xcrm.2024.101577</doi></cross_references></HashMap>